Skip to main content

Language(s) Spoken

English; Burmese

Joined Kelsey-Seybold

August 2021

Accepting New Patients?

Current patients only

To My Dear Patients:
I’m leaving Kelsey-Seybold’s Cancer Center to pursue a specific subspeciality in Oncology. My last day here will be Oct. 15, 2021. For questions regarding transition of care, phone the Hematology/Oncology Department at 713-442-1081, weekdays 8 a.m. to 5 p.m. I greatly appreciate the privilege of helping care for your health and I am sad to say goodbye. Read my full letter here.

Professional Background

Dr. Heidi Ko is a board-certified Internal Medicine physician specializing in Hematology/Oncology. She earned her Bachelor of Science in biology in 2011 from the University of North Carolina at Chapel Hill. She earned her Doctor of Osteopathic Medicine degree in 2015 from Rowan University School of Osteopathic Medicine in Stratford, N.J. She completed her internship and residency in Internal Medicine in 2018 at McGovern Medical School at UTHealth in Houston and completed her fellowship in Hematology and Oncology in 2021 at Montefiore Medical Center/Albert Einstein Center for Cancer Care in Bronx, N.Y.

Professional Associations

Dr. Ko is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American College of Physicians, and the American Osteopathic Association.

Hobbies and Interests

Dr. Ko enjoys traveling, cooking, fitness, and hiking with her dog. 

Fun Facts

The best advice Dr. Ko has ever received is “Take it one day at a time.”

Dr. Ko has traveled to many countries, but her favorite is Greece because of the good food, beaches, and islands.

Her guilty pleasure is watching Netflix reality shows.

Not everyone knows this about Dr. Ko, but she moved to the United States when she was 14 and since then has lived in Arkansas, North Carolina, New Jersey, New York, and Texas.

​I believe in educating my patients about their medical conditions so they will feel empowered and involved in a shared decision-making process. I also provide them with evidence-based care that will help guide an informed treatment decision. I truly enjoy getting to know my patients and their families and building strong, long-lasting relationships.

​​​​​​​​​By Phone

Our Contact Center is here to serve you, 24 hours a day, 7 days a week.

713-442-1080​​
​​ ​


Awards & Recognitions

Abstract of Third Highest Scientific Merit Award, The Greater New York and New England Chapters of the Society of Nuclear Medicine and Molecular Imaging, 2019

Publications

  • Manuscript “Clinical Utility of 18F-FDG-PET/CT in Staging Localized Breast Cancer prior to Initiating Preoperative Systemic Therapy” Selected as Press Release Article, JNCCN, 2020

Research

  • Ko H, Baghdadi Y, Love C, Sparano JA. Clinical Utility of 18F-FDG-PET/CT in Staging Localized Breast Cancer prior to Initiating Preoperative Systemic Therapy. Journal of the National Comprehensive Cancer Network 2020.10.6004/jnccn.2020.7592
  • Acuna A, Ko H, et al. The effect of everolimus on adipose tissue in patients with metastatic breast cancer. Journal of Clinical Oncology 2020.38.15_suppl.e13026.
  • Ko, H, Yan M, Gupta R, Kebbel K, Maiti A, Song J, Nates J, Overman MJ. Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit. The Oncologist. 2018; 10.164.
  • Short NJ, Kantarjian HM, Ko H, Khoury J, Ravandi F, Thomas D, Garcia-Manero G, Khouri M, Cortes J, Wierda W, Verstovsek S, Estrov Z, Ferrajoli A, Thompson P, Pierce S, Jabbour E. Outcomes of Adults with Relapsed or Refractory Burkitt and High-Grade Mature B-cell Leukemia/Lymphoma. American Journal of Hematology. 2017; 10.1002.
  • Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O’Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American Journal of Hematology. 2017;92:238–243.
  • Ko H, Maymani H, Rojas-Hernandez C. Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature. Journal of Medical Case Report, 2016; 10:175.